Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
NCT02899026 · GlaxoSmithKline · PHASE3 · withdrawn · last registry update 2017-11-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in polymyalgia rheumatica.” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-11-19Phase 3 first posted: CSL Behring, Clazakizumab + Physiologic saline solution (NCT03744910)
- 2018-10-09Results posted on the registry: Carla Greenbaum, MD, Siltuximab (NCT02641522)
- 2018-08-31Also stopped (withdrawn): GlaxoSmithKline, Sirukumab + Placebo (NCT02794519)
- 2018-03-29Results posted on the registry: Janssen Research & Development, LLC, Siltuximab (NCT01400503)
- 2018-02-05Results posted on the registry: Janssen Research & Development, LLC, Placebo + Placebo (NCT01606761)
- 2018-01-11Results posted on the registry: Janssen Research & Development, LLC, Placebo + Placebo (NCT01604343)
- 2017-12-04Results posted on the registry: Centocor, Inc., CNTO 136 100 mg + CNTO 136 50 mg (NCT00718718)
- 2017-09-14Results posted on the registry: Janssen Research & Development, LLC, adalimumab 40 mg + sirukumab 100 mg (NCT02019472)
- 2017-04-19Phase 3 first posted: R-Pharm International, LLC, Olokizumab 64 mg SC q4w + Olokizumab 64 mg SC q2w (NCT03120949)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision